HyperphosphatemiaPhase 3NCT01110629
Study in Chronic Kidney Disease (CKD) Not on Dialysis
A Phase 3 study testing Fosrenol (Lanthanum Carbonate, BAY77-1931) in people with Hyperphosphatemia, run by Bayer at 40 sites in Japan.
Trial summary
The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Hyperphosphatemia
- What is being tested?
- Fosrenol (Lanthanum Carbonate, BAY77-1931)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 143 participants
- Where
- 40 sitesJapan
- Study dates
- Jun 2010to Nov 2011
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female patients aged 20 years or above at the time of informed consent
- Chronic Kidney Disease patients with Epidermal growth factor receptor (eGFR) under 60 ml/min/1.73m2 (stage 3, 4 and 5) who have not been on dialysis
- Patients who had been in the care of a physician for Chronic Kidney Disease for >2 months and was not expected to begin dialysis for at least 4 months
- Patients with serum phosphate levels 5.6 mg/dL to 11.0 mg/dL at Week -4 (Visit 1) or Week -2 (Visit 2)
Who cannot join
- Patients with hypocalcemia or hypercalcemia (corrected serum calcium level of < 7.0 mg/dL or >/- 11.0 mg/dL) at Week -2 (Visit 2).
- Significant renal impairments
- Had acute renal failure within 3 months of Run-in period
Trial locations and contacts
40 sites in 1 country.
40 sites in 1 country
Japan40 sites
Study site
Amagasaki, Hyōgo, 660-0828
Study site
Anjo, Aichi-ken, 446-8602
Study site
Beppu, Oita Prefecture, 874-0011
Study site
Fujisawa, Kanagawa, 251-8550
Study site
Fukuoka, Fukuoka, 810-8563
Study site
Fukuoka, Fukuoka, 814-0180
Study site
Kamakura, Kanagawa, 247-8533
Study site
Kamogawa, Chiba, 296-0041
Study site
Kisarazu, Chiba, 292-8535
Study site
Kitakyushu, Fukuoka, 802-8555
Study site
Kitakyushu, Fukuoka, 805-0050
Study site
Koga, Fukuoka, 811-3195
Study site
Koto, Tokyo, 136-0075
Study site
Kurashiki, Okayama-ken, 710-8602
Study site
Kyoto, Kyoto, 612-8555
Study site
Meguro-ku, Tokyo, 152-8902
Study site
Minato-ku, Tokyo, 105-8471
Study site
Musashino, Tokyo, 180-8610
Study site
Nagoya, Aichi-ken, 455-8530
Study site
Nagoya, Aichi-ken, 457-8510
Study site
Nagoya, Aichi-ken, 460-0001
Study site
Nagoya, Aichi-ken, 466-8650
Study site
Ōita, Oita Prefecture, 870-0263
Study site
Okayama, Okayama-ken, 700-0013
Study site
Osaka, Osaka, 530-0012
Study site
Osaka, Osaka, 530-8480
Study site
Osaka, Osaka, 534-0021
Study site
Osaka, Osaka, 558-8558
Study site
Saga, Saga-ken, 840-0054
Study site
Sakai, Osaka, 591-8025
Study site
Sapporo, Hokkaido, 063-0005
Study site
Seto, Aichi-ken, 489-8642
Study site
Shinagawa, Tokyo, 141-8625
Study site
Shizuoka, Shizuoka, 421-0193
Study site
Tokushima, Tokushima, 770-0011
Study site
Toyohashi, Aichi-ken, 441-8021
Study site
Wakayama, Wakayama, 641-8510
Study site
Yatomi, Aichi-ken, 498-8502
Study site
Yokohama, Kanagawa, 231-8682
Study site
Yokohama, Kanagawa, 234-8503
About this study
Official title: Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia
The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis.
- Conditions
- Hyperphosphatemia
- Being tested
- Fosrenol (Lanthanum Carbonate, BAY77-1931), Placebo
- Keywords
- Chronic kidney disease not on dialysis, Lanthanum carbonate
- Medical subject headings
- Hyperphosphatemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fosrenol (Lanthanum Carbonate, BAY77-1931)Drug
Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
PlaceboDrug
daily dose: 3 tablets TID for 8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Experimental | Not described Receives: Drug: Fosrenol (Lanthanum Carbonate, BAY77-1931) |
| Arm 2 | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
The change from baseline in serum phosphate concentrations
Measured: Week 8
Secondary outcomes (4)
Achievement of target serum phosphate level (2.7 to 4.6 mg/dL)
Measured: Week 0, Week 2, Week 4, Week 6, Week 8
Change in serum Calcium x Phosphor product
Measured: Week 0, Week 2, Week 4, Week 6, Week 8
Serum intact PTH level
Measured: Week 0, Week 2, Week 4, Week 6, Week 8
Phosphate excretion in urine
Measured: Week 0, Week 4, Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2010 (estimated)
- Study startJun 2010
- Primary completionNov 2011
- Study completionNov 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HyperphosphatemiaStudies of the same condition, open and under way.
- More trials run by BayerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 143 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bayer
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Shire
- Responsible party
- Sponsor
- Investigators
- Bayer Study Director, Study director, Bayer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01110629
- Sponsor's protocol ID
- 14817
- Status last verified
- Oct 2014
- First submitted
- 23 Apr 2010
- Last updated
- 15 Oct 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
PubMed 40576086Takahara Y, Matsuda Y, Takahashi S, Shigematsu T; Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clin Nephrol. 2014 Sep;82(3):181-90. doi: 10.5414/cn108269.
PubMed 25079863
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia
- ClinicalTrials.gov ID
- NCT01110629
- Acronym / sponsor ID
- 14817
- Conditions
- Hyperphosphatemia
- Keywords
- Chronic kidney disease not on dialysis, Lanthanum carbonate
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 143 participants (actual)
- Lead sponsor
- BayerIndustry (pharma, biotech, devices)
- Collaborators
- Shire
- Study start
- Jun 2010
- Primary completion
- Nov 2011 (actual)
- Study completion
- Nov 2011 (actual)
- First posted
- 26 Apr 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Experimental | Drug: Fosrenol (Lanthanum Carbonate, BAY77-1931) |
| Arm 2 | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male and female patients aged 20 years or above at the time of informed consent
- Chronic Kidney Disease patients with Epidermal growth factor receptor (eGFR) under 60 ml/min/1.73m2 (stage 3, 4 and 5) who have not been on dialysis
- Patients who had been in the care of a physician for Chronic Kidney Disease for >2 months and was not expected to begin dialysis for at least 4 months
- Patients with serum phosphate levels 5.6 mg/dL to 11.0 mg/dL at Week -4 (Visit 1) or Week -2 (Visit 2)
Key exclusion criteria (3 listed)
- Patients with hypocalcemia or hypercalcemia (corrected serum calcium level of < 7.0 mg/dL or >/- 11.0 mg/dL) at Week -2 (Visit 2).
- Significant renal impairments
- Had acute renal failure within 3 months of Run-in period
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fosrenol (Lanthanum Carbonate, BAY77-1931)Daily dose: 750-2250mg 3 times a dayfor 8 weeks. | Drug | Arm 1 |
| Placebodaily dose: 3 tablets TID for 8 weeks. | Drug | Arm 2 |
Primary outcome
The change from baseline in serum phosphate concentrations
Time frame: Week 8
4 secondary outcomes
Achievement of target serum phosphate level (2.7 to 4.6 mg/dL)
Time frame: Week 0, Week 2, Week 4, Week 6, Week 8
Change in serum Calcium x Phosphor product
Time frame: Week 0, Week 2, Week 4, Week 6, Week 8
Serum intact PTH level
Time frame: Week 0, Week 2, Week 4, Week 6, Week 8
Phosphate excretion in urine
Time frame: Week 0, Week 4, Week 8
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2014.
- Derived from this study: PubMed 40576086Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
- Derived from this study: PubMed 25079863Takahara Y, Matsuda Y, Takahashi S, Shigematsu T; Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clin Nephrol. 2014 Sep;82(3):181-90. doi: 10.5414/cn108269.
Related trials for Hyperphosphatemia
Not yet recruitingObservational study
Tenapanor in Maintenance Hemodialysis Patients
Hyperphosphatemia, Maintenance Hemodialysis
Active, not recruitingPhase 3
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Hyperphosphatemia Patients on Hemodialysis
RecruitingObservational study
Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
Hyperphosphatemia
Recruiting
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Kidney Failure, Chronic, Hyperphosphatemia
RecruitingPhase 2
Phosphate in Acute Pancreatitis
Pancreatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bayer Study Director study director
Bayer
40 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Fosrenol (Lanthanum Carbonate, BAY77-1931) in people with Hyperphosphatemia, run by Bayer at 40 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Oct 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 40 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The change from baseline in serum phosphate concentrations (time frame: Week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01110629, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2014.